Device Week, Oct. 08, 2021 – Boston Scientific Acquisition, And Poor SPAC Float

Device Week, Oct. 08, 2021 – Boston Scientific Acquisition, And Poor SPAC Float In this edition of Device Week, Medtech Insight’s Reed Miller discusses Boston Scientific’s acquisition of Baylis, and what it means for its heart business. UK-based reporter Barnaby Pickering looks into LumiraDX’s recent float on the stock market, and why it might have been so poorly received. Medtech Insight articles addressing topics discussed in this episode: - Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products - LumiraDX Goes Public In SPAC Merger